CB1562

CHO-K1 IndcMET/EGFR

£9,000.00
£9,000.00
Tax included.
In Stock

CHO-K1 IndcMET/EGFR is an IndEx-2 stable cell line inducibly and independently expressing full length human cMET and EGFR.

IndEx-2 is RoukenCells' proprietary inducible expression system that enables precise, dose-dependent control of one or two target antigens within your chosen cell line. Using orthogonal chemically induced proximity switches, antigen expression can be independently tuned across a biologically relevant range, creating custom cell models for target validation, assay development and therapeutic screening.

Download our technical presentation here for more information and case studies.

FOR RESEARCH USE ONLY

Rouken Cells product packaging on a white background
Graph comparing EGFR expression in non-induced and CHO-K1 parental cells with inducer concentration.
Graph showing EGFR induction with inducer concentration on a log scale
Graph showing cMET induction with varying inducer concentrations for EGFR and cMET.
Graph showing cMET/EGFR matched induction with two curves on a log scale.
  • Rouken Cells product packaging on a white background
  • Graph comparing EGFR expression in non-induced and CHO-K1 parental cells with inducer concentration.
  • Graph showing EGFR induction with inducer concentration on a log scale
  • Graph showing cMET induction with varying inducer concentrations for EGFR and cMET.
  • Graph showing cMET/EGFR matched induction with two curves on a log scale.
Rouken Cells product packaging on a white background
Graph comparing EGFR expression in non-induced and CHO-K1 parental cells with inducer concentration.
Graph showing EGFR induction with inducer concentration on a log scale
Graph showing cMET induction with varying inducer concentrations for EGFR and cMET.
Graph showing cMET/EGFR matched induction with two curves on a log scale.
Specification
Inducible Receptor
cMET
EGFR
CD Designation
CD340
CD332
Gene name
MET
EGFR
Aliases
CD340, MET, HGFR
CD332, EGFR, ERBB1, HER1
Uniprot ID
P08581
P00533
Receptor Species
Homo sapiens
Homo sapiens
Cell Line Background
CHO-K1
Target Information and Further Details
cMET (hepatocyte growth factor receptor, MET) and EGFR (epidermal growth factor receptor, ERBB1) are highly validated receptor tyrosine kinase targets that play central roles in oncogenic signalling across multiple solid tumour types. EGFR is a member of the ERBB family of receptors and regulates key cellular processes including proliferation, survival, and differentiation through ligand-induced dimerisation and activation of downstream pathways such as MAPK, PI3K–AKT, and JAK–STAT. Aberrant EGFR signalling driven by receptor overexpression, amplification, or activating mutations is a hallmark of cancers including non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck squamous cell carcinoma. Consequently, EGFR has been extensively targeted by therapeutic antibodies such as cetuximab and panitumumab, as well as multiple generations of small-molecule tyrosine kinase inhibitors.

cMET is the receptor for hepatocyte growth factor (HGF) and functions as a key regulator of cell motility, survival, and invasive growth. Activation of the HGF–MET signalling axis promotes tumour progression through stimulation of pathways including PI3K–AKT, RAS–MAPK, and STAT3. Dysregulation of cMET signalling can arise through gene amplification, overexpression, or exon 14 skipping mutations and has been implicated in cancers such as NSCLC, gastric cancer, and hepatocellular carcinoma. Therapeutic targeting of cMET includes monoclonal antibodies and small-molecule inhibitors such as capmatinib and tepotinib.

Importantly, EGFR and cMET signalling pathways are highly interconnected, and compensatory cMET activation is a well-established mechanism of resistance to EGFR-targeted therapies. Co-expression of these receptors can drive tumour growth through receptor cross-talk and heterodimerisation, making the EGFR–cMET axis an attractive target for combination and bispecific therapeutic strategies aimed at overcoming pathway redundancy and resistance.

The CHO-K1 cMET/EGFR IndEx-2 cell line enables independent, inducible control of both cMET and EGFR expression, providing a robust and tunable system to study receptor co-expression, evaluate binding and avidity of mono- or bispecific molecules, and assess functional responses across defined antigen density combinations relevant to EGFR×cMET therapeutic development
Performance Data
Graph comparing EGFR expression in non-induced and CHO-K1 parental cells with inducer concentration.

Figure 1 – Histograms of EGFR Induction at 0-300 µM Inducer 1.

Figure 2 – Histograms of cMET Induction at 0-300 µM Inducer 2.

Graph showing EGFR induction with inducer concentration on a log scale

Figure 3 – Quantification of orthogonal EGFR Induction at 0-300 µM Inducer 1.

Graph showing cMET induction with varying inducer concentrations for EGFR and cMET.

Figure 4 – Quantification of orthogonal cMET Induction at 0-300 µM Inducer 2.

Graph showing cMET/EGFR matched induction with two curves on a log scale.

Figure 5 – Quantification of dual CD19/CD22 Induction at 0-300 µM Inducer 1/Inducer 2.

* Cells were then stained with a labelled antibody and expression levels quantified using a bead-based quantification kit. Specific induction conditions should be further defined by the user. Cell line suitable for preclinical research and development use only.

Shipping Details

Supplied as 1 vial of >3 million viable cells.

* Please note that US import permits for CHO-K1 cell products are the responsibility of the US-based recipient/importer. RoukenCells is happy to provide supporting documentation (e.g. product descriptions and noninfectious statements) to assist with the import process.

Cell Line Datasheet

Access detailed product specifications, user guides and technical documentation in PDF format.

Download PDF

Related products

Take a moment to explore selections tailored just for you.

Explore Now